StreetInsider.com News Articles

Form 8-K FILANA THERAPEUTICS, For: Mar 10

Tue, 10 Mar 2026 08:16:00 -0400

si-local-file:///var/storage/secattach/20260310/26135882.html

Form 8-K FILANA THERAPEUTICS, For: Mar 10

Tue, 10 Mar 2026 08:16:00 -0400

si-local-file:///var/storage/secattach/20260310/26135882.html

Cassava Sciences changes name to Filana Therapeutics

Tue, 10 Mar 2026 08:00:15 -0400

Cassava Sciences Inc. (NASDAQ: SAVA) announced it will rebrand as Filana Therapeutics Inc., with the new ticker symbol "FLNA" beginning trading on the Nasdaq Capital Market on March 11, 2026.

The Austin, Texas-based biotechnology company said the name change reflects its focus on developing medicines to modulate the filamin A protein for treating central nervous system disorders, particularly tuberous sclerosis complex (TSC)-related epilepsy.

"The launch of Filana Therapeutics represents a new beginning for our Company," said Rick Barry, president and chief executive officer. "Growing evidence suggests that filamin A is an important regulator of neuronal development and that modulating filamin A may

Cassava Sciences changes name to Filana Therapeutics

Tue, 10 Mar 2026 08:00:15 -0400

Cassava Sciences Inc. (NASDAQ: SAVA) announced it will rebrand as Filana Therapeutics Inc., with the new ticker symbol "FLNA" beginning trading on the Nasdaq Capital Market on March 11, 2026.

Cassava Sciences Announces Name Change to Filana Therapeutics, Inc.

Tue, 10 Mar 2026 08:00:00 -0400

New corporate identity reflects the Company’s mission to develop novel medicines to modulate filamin A and address unmet needs in treating TSC-related epilepsy

Filana Therapeutics to begin trading under “FLNA” effective March 11, 2026

AUSTIN, Texas, March 10, 2026 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (NASDAQ: SAVA) today announced the rebranding of the Company, with a name change to Filana Therapeutics, Inc. (“Filana Therapeutics”, or the “Company”). The new name and corporate brand reflect the Company’s strategic focus on developing novel medicines to modulate the filamin A protein for the treatment of central

Cassava Sciences Announces Name Change to Filana Therapeutics, Inc.

Tue, 10 Mar 2026 08:00:00 -0400

New corporate identity reflects the Company’s mission to develop novel medicines to modulate filamin A and address unmet needs in treating TSC-related epilepsy

Filana Therapeutics to begin trading under “FLNA” effective March 11, 2026

Cassava Sciences Announces Name Change to Filana Therapeutics, Inc.

Tue, 10 Mar 2026 08:00:00 -0400

New corporate identity reflects the Company’s mission to develop novel medicines to modulate filamin A and address unmet needs in treating TSC-related epilepsy

Filana Therapeutics to begin trading under “FLNA” effective March 11, 2026

Cassava Sciences Announces Name Change to Filana Therapeutics, Inc.

Tue, 10 Mar 2026 08:00:00 -0400

New corporate identity reflects the Company’s mission to develop novel medicines to modulate filamin A and address unmet needs in treating TSC-related epilepsy

Filana Therapeutics to begin trading under “FLNA” effective March 11, 2026

Form 8-K CASSAVA SCIENCES INC For: Feb 19

Thu, 19 Feb 2026 08:15:00 -0400

si-local-file:///var/storage/secattach/20260219/26026457.html

Form 8-K CASSAVA SCIENCES INC For: Feb 19

Thu, 19 Feb 2026 08:15:00 -0400

si-local-file:///var/storage/secattach/20260219/26026457.html

Cassava Sciences announces end of DOJ investigation

Thu, 19 Feb 2026 08:01:19 -0400

Cassava Sciences Inc. (NASDAQ: SAVA) announced that the U.S. Department of Justice has closed its investigation into the company regarding allegations of research misconduct. The DOJ Fraud Section inquiry related to allegations described in United States v. Wang, an indictment that was dismissed with prejudice in October 2025.

The Austin-based biotechnology company previously settled with the U.S. Securities and Exchange Commission in September 2024 over negligence-based disclosure charges, paying a monetary penalty without admitting or denying the allegations. The company stated it cooperated fully with both investigations.

The closures end federal investigations into Cassava Sciences by both the DOJ and SEC. The

Cassava Sciences announces end of DOJ investigation

Thu, 19 Feb 2026 08:01:19 -0400

The closures end federal investigations into Cassava Sciences by both the DOJ and SEC. The

Cassava Announces Closure of U.S. Department of Justice Investigation

Thu, 19 Feb 2026 08:00:00 -0400

AUSTIN, Texas, Feb. 19, 2026 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (NASDAQ: SAVA, “Cassava”, the “Company”), a biotechnology company focused on developing novel, investigational treatments for central nervous system (CNS) disorders such as Tuberous Sclerosis Complex (TSC)-related epilepsy, today announced that the U.S. Department of Justice Fraud Section (DOJ) has closed its inquiry into the Company regarding allegations of research misconduct as described in the indictment in United States v. Wang, 8:24-cr-000211-TDC (D. Md.). That indictment was dismissed with prejudice by DOJ on October 23, 2025.

As previously disclosed, the Company reached a settlement with the

Cassava Announces Closure of U.S. Department of Justice Investigation

Thu, 19 Feb 2026 08:00:00 -0400

As previously disclosed, the Company reached a settlement with the

Cassava Sciences (SAVA) 28K contracts of January 23 weekly 2.5 calls trade, share price up 9%

Wed, 21 Jan 2026 14:57:06 -0400

Cassava Sciences (NASDAQ: SAVA) 30-day option implied volatility is at 141; compared to its 52-week range of 78 to 135. Call put ratio 480 calls to 1 put with a focus on 28K contracts of January 23 weekly 2.5 calls as share price up 9%.

Cassava publishes phase 3 simufilam alzheimer's trial results in journal

Tue, 13 Jan 2026 08:01:03 -0400

Cassava Sciences Inc. (NASDAQ: SAVA) announced the publication of results from two phase 3 clinical trials of simufilam for Alzheimer's disease in the Journal of Prevention of Alzheimer's Disease. The studies, RETHINK-ALZ and REFOCUS-ALZ, did not meet their pre-specified co-primary, secondary, or exploratory biomarker endpoints, as previously disclosed by the company.

RETHINK-ALZ randomized 804 people with mild to moderate Alzheimer's disease, with topline results reported in November 2024. REFOCUS-ALZ randomized 1,125 patients, with results reported in March 2025. Cassava has discontinued development of simufilam for Alzheimer's disease and plans no further investment in the program.

The trials were designed as multi-center, double-blinded,

Cassava Announces Publication of Peer-Reviewed Phase 3 Results for Simufilam in Alzheimer’s Disease in the Journal of Prevention of Alzheimer’s Disease

Tue, 13 Jan 2026 08:00:00 -0400

As previously disclosed, the studies did not meet pre-specified co-primary, secondary, or exploratory biomarker endpoints

The paper provides a detailed analysis of the RETHINK-ALZ and REFOCUS-ALZ studies and confirms simufilam’s favorable safety profile in these studies

Exploratory post-hoc analyses offer informative insights

AUSTIN, Texas, Jan. 13, 2026 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (NASDAQ: SAVA, “Cassava”, the “Company”), a biotechnology company focused on developing novel, investigational treatments for central nervous system (CNS) disorders such as Tuberous Sclerosis Complex (TSC)-related epilepsy, today announced publication of the article Phase

Cassava Announces Publication of Peer-Reviewed Phase 3 Results for Simufilam in Alzheimer’s Disease in the Journal of Prevention of Alzheimer’s Disease

Tue, 13 Jan 2026 08:00:00 -0400

As previously disclosed, the studies did not meet pre-specified co-primary, secondary, or exploratory biomarker endpoints

The paper provides a detailed analysis of the RETHINK-ALZ and REFOCUS-ALZ studies and confirms simufilam’s favorable safety profile in these studies

Exploratory post-hoc analyses offer informative insights

AUSTIN, Texas, Jan. 13, 2026 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (NASDAQ: SAVA, “Cassava”, the “Company”), a biotechnology company focused on developing novel, investigational treatments for central nervous system (CNS) disorders such as Tuberous Sclerosis Complex (TSC)-related epilepsy, today announced publication of the article Phase

Form 8-K CASSAVA SCIENCES INC For: Dec 19

Tue, 23 Dec 2025 08:46:00 -0400
si-local-file:///var/storage/secattach/20251223/25773536.html

Form 8-K CASSAVA SCIENCES INC For: Dec 19

Tue, 23 Dec 2025 08:46:00 -0400
si-local-file:///var/storage/secattach/20251223/25773536.html

Cassava Sciences agrees to pay $31.25 million to settle class action suit

Tue, 23 Dec 2025 08:02:34 -0400

Cassava Sciences Inc. (NASDAQ: SAVA) announced it reached an agreement to settle consolidated securities class action litigation for $31.25 million. The lawsuit was filed in 2021 in the United States District Court for the Western District of Texas Austin Division.
The settlement covers all purchasers or acquirers of company common stock or call options, or sellers of put options, between September 14, 2020 and October 12, 2023, subject to certain exclusions. The agreement resolves all claims and causes of action that have been or could be asserted by the plaintiffs and plaintiff class.
The biotechnology company, which focuses on developing treatments for

Cassava Sciences agrees to pay $31.25 million to settle class action suit

Tue, 23 Dec 2025 08:02:34 -0400

Cassava Sciences Inc. (NASDAQ: SAVA) announced it reached an agreement to settle consolidated securities class action litigation for $31.25 million. The lawsuit was filed in 2021 in the United States District Court for the Western District of Texas Austin Division.
The settlement covers all purchasers or acquirers of company common stock or call options, or sellers of put options, between September 14, 2020 and October 12, 2023, subject to certain exclusions. The agreement resolves all claims and causes of action that have been or could be asserted by the plaintiffs and plaintiff class.
The biotechnology company, which focuses on developing treatments for

Cassava Sciences agrees to pay $31.25 million to settle class action suit

Tue, 23 Dec 2025 08:02:34 -0400

Cassava Sciences Inc. (NASDAQ: SAVA) announced it reached an agreement to settle consolidated securities class action litigation for $31.25 million. The lawsuit was filed in 2021 in the United States District Court for the Western District of Texas Austin Division.
The settlement covers all purchasers or acquirers of company common stock or call options, or sellers of put options, between September 14, 2020 and October 12, 2023, subject to certain exclusions. The agreement resolves all claims and causes of action that have been or could be asserted by the plaintiffs and plaintiff class.
The biotechnology company, which focuses on developing treatments for

Cassava Announces Agreement to Settle Securities Class Action Litigation

Tue, 23 Dec 2025 08:00:00 -0400

AUSTIN, Texas, Dec. 23, 2025 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (NASDAQ: SAVA, “Cassava”, the “Company”), a biotechnology company focused on developing novel, investigational treatments for central nervous system (CNS) disorders such as Tuberous Sclerosis Complex (TSC)-related epilepsy, today announced that it has reached a definitive agreement to resolve the previously disclosed consolidated securities class action litigation pending in the United States District Court for the Western District of Texas Austin Division (In re Cassava Sciences, Inc. Securities Litigation, No. 1:21-cv-00751-DAE) (the “Consolidated Securities Action”). This lawsuit was originally filed in 2021.

Under the agreement,

Cassava Announces Agreement to Settle Securities Class Action Litigation

Tue, 23 Dec 2025 08:00:00 -0400

AUSTIN, Texas, Dec. 23, 2025 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (NASDAQ: SAVA, “Cassava”, the “Company”), a biotechnology company focused on developing novel, investigational treatments for central nervous system (CNS) disorders such as Tuberous Sclerosis Complex (TSC)-related epilepsy, today announced that it has reached a definitive agreement to resolve the previously disclosed consolidated securities class action litigation pending in the United States District Court for the Western District of Texas Austin Division (In re Cassava Sciences, Inc. Securities Litigation, No. 1:21-cv-00751-DAE) (the “Consolidated Securities Action”). This lawsuit was originally filed in 2021.

Under the agreement,